Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male participants. This study will also evaluate the safety and tolerability when vimseltinib is co-administered with rosuvastatin in healthy male participants. This study will last approximately 26 days.

Key facts

Study ID

NCT07158398

Run by

Deciphera Pharmaceuticals, LLC

People needed

20

Starts

2025-10-31

Expected to finish

2025-12-08

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Participants are in good general health, as required by the protocol and as determined by Principal Investigator.
• Body mass index (BMI) from 18 to 32 kilogram per square meter (kg/m\^2).
• Adequate organ function and blood and urine tests, as required by the protocol and as determined by Principal Investigator.

You may not qualify if…

• History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator.
• Unwilling or unable to comply with the requirements of the protocol.
• Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.

Where it is running

• Dr. Vince Clinical Research — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.